Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.69 |
| ▸ | MMP12 | P39900 | 2/20 | 0.55 |
| ▸ | MMP13 | P45452 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29250508 | 0.91 | CA2 (0.60) | CA2MMP12MMP13IDO1CA1 | |
| SCHEMBL14495267 | 0.90 | CA2 (0.77) | CA2MMP12MMP13IDO1CA1 | |
| SCHEMBL7388755 | 0.89 | CA2 (0.58) | CA2MMP12MMP13IDO1CA1 | |
| SCHEMBL9180265 | 0.89 | CA2 (0.58) | CA2MMP12MMP13IDO1CA1 | |
| SCHEMBL3247748 | 0.88 | CA2 (0.62) | CA2MMP12MMP13IDO1CA1 | |
| SCHEMBL4175756 | 0.88 | CA2 (0.62) | CA2MMP12MMP13IDO1CA1 | |
| SCHEMBL8788953 | 0.86 | CA2 (0.60) | CA2MMP12MMP13IDO1CA1 | |
| SCHEMBL5863378 | 0.85 | KEAP1 (0.61) | CA2MMP12MMP13ALDH1A1MMP1 | |
| SCHEMBL777369 | 0.85 | CA2 (0.71) | CA2ALDH1A1KDM4EMAPTHTR2A | |
| SCHEMBL12040755 | 0.84 | CA2 (0.53) | CA2MMP12MMP13HPGDMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103414-A1 | METHOD FOR OBSERVING MICROSCOPIC FORMATION PROCESS OF POROUS MEMBRANE PREPARED BY PHASE SEPARATION METHOD | 中国科学院大连化学物理研究所 | 2026-05-21 | — | — | WO | claimed |
| CN-122055826-A | Secondary battery, method for manufacturing the same, and power consumption device | 香港科技大学 | 2026-05-15 | — | — | CN | claimed |
| CN-122050577-A | Non-solvent screening method for preparing polymer porous membrane by non-solvent induced phase separation method | 中国科学院大连化学物理研究所 | 2026-05-15 | — | — | CN | claimed |
| CN-122042335-A | Method for observing microscopic formation process of porous membrane prepared by phase separation method | 中国科学院大连化学物理研究所 | 2026-05-15 | — | — | CN | claimed |
| CN-114914537-B | Electrolyte of full-climate battery with high-nickel anode material | 北京科技大学 | 2025-05-16 | — | — | CN | claimed |
| CN-119663296-A | Hydrocarbon cleaning agent for preventing metal surface from oxidation and preparation method thereof | 诺而曼环保科技（江苏）有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119638606-A | Separation method of tertiary dodecyl mercaptan reaction liquid | 万华化学集团股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| WO-2024234610-A1 | ELECTROLYTE FOR MAGNESIUM ION BATTERY, PREPARATION METHOD THEREFOR, AND MAGNESIUM ION BATTERY | 清华大学 | 2024-11-21 | — | — | WO | claimed |
| CN-115377489-B | Preparation method of wide-temperature-range electrolyte for lithium ion battery | 中国人民解放军军事科学院防化研究院 | 2024-09-13 | — | — | CN | claimed |
| CN-118173889-A | Electrolyte, lithium ion battery and electricity utilization device | 清陶(昆山)能源发展集团股份有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-110846154-A | Plate-attachment-preventing cleaning agent for OLED organic evaporation equipment and application | 安徽富乐德科技发展有限公司 | 2020-02-28 | — | — | CN | claimed |
| CN-107553646-A | A kind of method for reducing Formaldehye Emission from Wood Products | 安徽阜南县万家和工艺品有限公司 | 2018-01-09 | — | — | CN | claimed |
| EP-2016942-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORPORATION (US) | 2009-01-21 | — | — | EP | claimed |
| EP-1691797-A2 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITOR AND PHOSPHODIESTERASE 4 INHIBITOR AND METHOD | Pharmacia Corporation (US) | 2006-08-23 | — | — | EP | claimed |
| US-20050187278-A1 | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors | PHARMACIA CORPORATION (US) | 2005-08-25 | — | — | US | claimed |
| WO-2005041864-A2 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITOR AND PHOSPHODIESTERASE 4 INHIBITOR AND METHOD | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | claimed |
| WO-2005020926-A2 | TREATMENT OR PREVENTION OF VASCULAR DISORDERS WITH COX-2 INHIBITORS IN COMBINATION WITH CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | PHARMACIA CORPORATION (US) | 2005-03-10 | — | — | WO | claimed |
| EP-1242082-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORPORATION (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020054899-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORP. | 2002-05-09 | — | — | US | claimed |
| WO-2001043743-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP. (US) | 2001-06-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187278-A1 | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors | PDE2A, PDE3A, PDE3B | CA2 195/4885MMP12 821/4885MMP13 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.